The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Stephen Hiscox

Welsh School of Pharmacy

Cardiff University




Name/email consistency: high



  • Welsh School of Pharmacy, Cardiff University, Wales, UK. 2009 - 2012
  • Welsh School of Pharmacy, Cardiff University, Redwood Building, Kind Edward VII Avenue, UK. 2004 - 2011
  • Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, Wales, UK. 2009


  1. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. Hiscox, S., Baruha, B., Smith, C., Bellerby, R., Goddard, L., Jordan, N., Poghosyan, Z., Nicholson, R.I., Barrett-Lee, P., Gee, J. BMC. Cancer (2012) [Pubmed]
  2. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Hiscox, S., Barnfather, P., Hayes, E., Bramble, P., Christensen, J., Nicholson, R.I., Barrett-Lee, P. Breast Cancer Res. Treat. (2011) [Pubmed]
  3. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Hiscox, S., Jordan, N.J., Smith, C., James, M., Morgan, L., Taylor, K.M., Green, T.P., Nicholson, R.I. Breast Cancer Res. Treat. (2009) [Pubmed]
  4. Aromatase inhibitors in breast cancer. Hiscox, S., Davies, E.L., Barrett-Lee, P. Maturitas (2009) [Pubmed]
  5. Src inhibitors in breast cancer therapy. Hiscox, S., Nicholson, R.I. Expert Opin. Ther. Targets (2008) [Pubmed]
  6. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Hiscox, S., Jordan, N.J., Morgan, L., Green, T.P., Nicholson, R.I. Clin. Exp. Metastasis (2007) [Pubmed]
  7. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Hiscox, S., Jiang, W.G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R., Barrow, D., Nicholson, R.I. Int. J. Cancer (2006) [Pubmed]
  8. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Hiscox, S., Morgan, L., Green, T.P., Barrow, D., Gee, J., Nicholson, R.I. Breast Cancer Res. Treat. (2006) [Pubmed]
  9. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Hiscox, S., Jordan, N.J., Jiang, W., Harper, M., McClelland, R., Smith, C., Nicholson, R.I. Endocr. Relat. Cancer (2006) [Pubmed]
  10. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Hiscox, S., Morgan, L., Green, T., Nicholson, R.I. Endocr. Relat. Cancer (2006) [Pubmed]
  11. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Hiscox, S., Morgan, L., Barrow, D., Dutkowskil, C., Wakeling, A., Nicholson, R.I. Clin. Exp. Metastasis (2004) [Pubmed]
WikiGenes - Universities